US20030104989A1 - Carrier polymers migrating into target organs and drug-containing polymers - Google Patents

Carrier polymers migrating into target organs and drug-containing polymers Download PDF

Info

Publication number
US20030104989A1
US20030104989A1 US10/283,047 US28304702A US2003104989A1 US 20030104989 A1 US20030104989 A1 US 20030104989A1 US 28304702 A US28304702 A US 28304702A US 2003104989 A1 US2003104989 A1 US 2003104989A1
Authority
US
United States
Prior art keywords
formula
group
polymer
glutamic acid
pge
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/283,047
Inventor
Mitsuru Hashida
Ken Akamatsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Priority to US10/283,047 priority Critical patent/US20030104989A1/en
Publication of US20030104989A1 publication Critical patent/US20030104989A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/48—Polymers modified by chemical after-treatment

Definitions

  • the present invention relates to saccharide-modified polymers which are useful as carriers capable of migrating into target organs (cells), drug-containing polymers using them and the process for the preparation thereof.
  • the drug delivery systems into the target organs comprising low-molecular drugs bonded to high-molecular compounds as carriers capable of migrating into target organs have been studied in order to obtain the aimed pharmaceutical effect of the drugs on the target organs and to reduce the side effects of the drugs on the other organs.
  • poly-L-glutamic acid derivatives wherein a part of or all of the consisting peptide bonds in the poly-L-glutamic acid of the formula
  • [0006] is useful as a carrier of drugs capable of migrating into liver in the Japanese Patent Application Kokai Hei 7-228688.
  • the drugs have been conjugated to carboxyl group in the said glutamic acid via amide bond, ester bond or ion bond etc. directly.
  • Vitamin K5 is described as an example of drugs in this publication.
  • polymers of PGE 1 -containing L-glutamic acid derivative (abbreviated as polymer PA) of the formula
  • [0008] is as high-molecule prodrug of PGE 1 capable of migrating into liver in International. J. Pharmaceutics, 155, 65-74 (1997).
  • the drug (PGE 1 ) is conjugated to L-glutamic acid via amide bond through ethylenediamine (—NH—CH 2 CH 2 —NH—) as a spacer.
  • the present inventors have dissolved such a problem by using hydrazine (—NH—NH—) instead of ethylenediamine (—NH—CH 2 CH 2 —NH—) as a spacer in the reaction of drugs (e.g. PGE 1 ) and L-glutamic acid. That is to say, the reaction to introduce the drugs (PGE 1 ) is carried out in a weak acidic condition, so it is possible to introduce the drugs constantly, even if it is unstable in an alkaline condition. Based on this reaction, they have improved the introducing rate of drugs (e.g. PGE 1 ) into poly-L-glutamic acid, and then succeeded in synthesis of drugs-containing polymers showing the superior effect.
  • drugs e.g. PGE 1
  • L-glutamic acid ethylenediamine
  • any compounds can be introduced into the polymer constantly by using this reaction.
  • the polymer using hydrazine of the present invention shows superiority in both accumulation of drugs into liver after administration and effects of drugs (cytoprotective activity of PGE 1 ) to the polymers using ethylelendiamine.
  • the present invention relates to
  • G is a modified saccharide capable of conjugating to hydrazine, m is 1 when is a single bond and m is 0 when is a double bond.
  • Polymer P1 is a carrier polymer capable of migrating into target organs (cells) and Polymer P2 is a drug-containing polymer, which is obtained by utilizing the said carrier polymer, capable of migrating into target organs (cells).
  • the delivery of the polymer of the present invention into target organs (cells) depends upon the saccharide (represented by G) conjugated to glutamic acid. It is known that various kinds of receptors for saccharides exist in organs (cells) and, new receptors may be found in the future study. It is possible to obtain the drug delivery system into target organs (cells) by choice of saccharide (G) capable of conjugating to the aimed organs (cells) including such known or new receptors.
  • [0030] is a group of the formula of (G 1 ), (G 2 ) and (G 3 ) described hereinafter.).
  • the delivery of the polymer of the present invention into target organs (cells) depends upon the terminal saccharide.
  • the terminal saccharide of lactose which is one of disaccharide (corresponds to Polymer P1 and P2 of the present invention in which
  • [0031] is a group of the formula (G 4a ) and (G 5a ).) is galactose, so such a polymer migrates into liver parenchymal cell mainly.
  • the aimed saccharide natural ones or artificial ones which are synthesized may be used.
  • the symbol d in the formula (A) in Polymer P1 and P2 of the present invention means the degree of polymerization of L-glutamic acid which is a unit of the polymer of the present invention and it is an integer of 20 ⁇ 500, preferably 40 ⁇ 300 and more preferably 50 ⁇ 150.
  • the number of replacement of group of the formula (B) in Polymer P1 (corresponds to y 2 described hereinafter.) is 5 ⁇ 250 and preferably 5 ⁇ 50.
  • the number of replacement of group of the formula (C) (corresponds to z 2 described hereinafter.) is 10 ⁇ 100, and preferably 20 ⁇ 60.
  • the number of replacement of group of the formula (B) in Polymer P2 (corresponds to y 3 described hereinafter.) is 0 ⁇ 250, and preferably 0 ⁇ 50.
  • the number of replacement of group of the formula (C) (corresponds to z 3 described hereinafter.) is 10 ⁇ 100, and preferably 20 ⁇ 60.
  • the number of replacement of group of the formula (D) (corresponds to w 3 described hereinafter.) is 1 ⁇ 20, and preferably 1 ⁇ 10.
  • the average of molecule weight of Polymer P1 is 5,000 ⁇ 150,000.
  • [0039] is a group of the formula (G 1 ), (G 2 ) and (G 3 ) described hereinafter.) or disaccharide such as lactose derivative
  • [0040] is a group of the formula (G 4a ) and (G 5a ) described hereinafter.) is 5,000 ⁇ 100,000 and preferably 10,000 ⁇ 30,000.
  • C1-6 alkyl in the formula (A) in Polymer P1 and P2 means methyl, ethyl, propyl, butyl, pentyl or hexyl or its isomer.
  • Each R is preferably, i) hydrogen or the said C1 ⁇ 6 alkyl (when multiple R are alkyl, they are the same.), ii) hydrogen or benzyl, or iii) hydrogen only, and more preferably, iii) hydrogen only.
  • the sacchardie represented by G in the formula (C) in Polymer P1 and P2 may be selected in accordance with the receptors which are know or may be found in the future study exist in the organs (cells), as mentioned before.
  • the modified saccharides represented by G capable of conjugating to hydrazine include, for example, 2-iminoethyl-1-thiosaccharide derivatives and saccharides comprising a group wherein the linkage is cleaved etc.
  • the said 2-iminoethyl-1-thiosaccharide derivative represented by G include, for example, a group of the formula (if it is represented by
  • the said saccharide containing a group, wherein the linkage is cleaved, represented by G include, for example, group of the formula (if it is represented by
  • 1 ⁇ 10 of saccharide represented by Q in the above formula include, for example, the saccharide of the formula
  • each p, q and r is 0 or an integer of 1 ⁇ 9.
  • galactose, mannose and fucose corresponds to a group in which each p, q, r is 0 in the above formula
  • more preferably galactose are preferably galactose.
  • [0050] is preferably a group of the formula
  • glutamic acid and drugs represented by D is conjugated via various kinds of bonds such as hydorazon bond or amide bond etc. through hydrazino (—NH—NH 2 ) which is introduced to L-glutamic acid in accordance with the structure of drugs.
  • the drugs represented by D included any drugs, and preferably, the drug which is unstable in an alkaline condition.
  • Such an alkaline condition means pH8 ⁇ 11 preferably.
  • Concrete drugs include PGs (e.g. PGEs, PGFs, PGDs), PGIs, naphthyloxyacetic acid derivatives, bicycloalkanoic acid derivatives, guanidinobenzoic acid derivatives, rhodanine acetic acid derivatives, cinnamoic acid derivatives, valproic acid derivatives, Vitamins, anti-allergic agents, anti-vital, anti-cancer agents etc.
  • PGs e.g. PGEs, PGFs, PGDs
  • PGIs naphthyloxyacetic acid derivatives
  • bicycloalkanoic acid derivatives guanidinobenzoic acid derivatives
  • guanidinobenzoic acid derivatives rhodanine acetic acid derivatives
  • cinnamoic acid derivatives valproic acid derivatives
  • Vitamins e.g. PGEs, PGFs, PGDs
  • PGIs e.g. PGIs, naph
  • PGs include natural PG such as PGE 1 , PGE 2 , PGF 1 ⁇ , PGF 2 ⁇ , PGD 1 , PGD 2 etc. and its derivatives.
  • natural PGE 1 and PGE 2 are the compounds shown by the following structures, respectively:
  • PGD 1 and PGD 2 are the compounds shown by the following structures, respectively:
  • the concrete PGs include the compounds of the following formula
  • R c is hydrogen or various kinds of substituents of carboxyl group such as C1 ⁇ 12 alkyl, benzyl etc.,
  • A is C2 ⁇ 10 alkylene (1) in which optional carbon atom may be replaced with CO and/or (2) may have one or more double bond(s),
  • B is C1 ⁇ 10 alkyl , C2 ⁇ 10 alkenyl or C2 ⁇ 10 alkynyl may be substituted with phenyl, phenoxy or cycloalkyl (wherein each ring may be substituted with C1 ⁇ 6 alkyl , C2 ⁇ 6 alkenyl, C2 ⁇ 6 alkynyl, C1 ⁇ 6 alkoxy or halogen etc.),
  • [0063] is ethylene, trans-vinylene or ethynylene.).
  • PGs include preferably PGEs or PGDs (the compounds of the formula
  • PGEs the compounds of the formula
  • Such compounds include PGE 1 , PGE 2 , 17,20-dimethyl-trans- ⁇ 2 -PGE 1 , 6-keto-17,20-dimethyl-trans- ⁇ 2 -PGE 1 methyl ester, 16,16-dimethyl-trans- ⁇ 2 -PGE 1 methyl ester etc.
  • PGEs and PGDs may be conjugated to L-glutamic acid via hydorazon bond at the 9th and 11th position carbon, respectively.
  • PGE 1 may be conjugated to L-glutamic acid as shown as following structure:
  • PGFs may be conjugated to L-glutamic acid via amide bond between the carboxyl group and amine group of hydrazine which is introduced.
  • PGIs include natural PGI 2 and its derivatives, for example, the compounds disclosed in Japanese Patent Application Kokai Sho 54-130543 and Sho 55-64541 (corresponding to GBP-2017699). PGls may be conjugated to L-glutamic acid via amide bond.
  • Naphthyloxyacetic acid derivatives include, for example, the compounds disclosed in Japanese Patent Application Kokai Hei 6-87811 (corresponding to U.S. Pat. No. 5,480,998), for example, [5-[2-[1-phenyl-(3-pyridyl)methylildenaminooxy]ethyl]-7,8-dihydronahthalene-1-yloxy]acetic acid shown by the formula
  • Such a naphthyloxyacetic acid compound may be conjugated to L-glutamic acid via amide bond at the terminal amino group of hydrazine as shown by the following structure:
  • Bicycloalkanoic acid derivatives include, for example, the compounds disclosed in Japanese Patent Application Hei 9-140959.
  • Guanidinobenzoic acid derivatives include, for example, the compounds disclosed in Japanese Patent Application Kokai Sho 51-138642 (corresponding to U.S. Pat. No. 4,021,472).
  • Rhodanine acetic acid derivatives include, for example, the compounds disclosed in Japanese Patent Application Kokai Sho 57-40478 (corresponding to U.S. Pat. No. 4,464,382).
  • Cinnamoic acid derivatives include, for example, the compounds disclosed in 1) Japanese Patent Application Kokai Sho 55-313 (corresponding to U.S. Pat. No. 4,226,878), 2) Japanese Patent Application Kokai Sho 57-131769 (corresponding to U.S. Pat. No. 4,607,046) and 3) International Patent Application No. PCT/JP97/04593.
  • Valproic acid derivatives include, for example, the compounds disclosed in Japanese Patent Application Kokai Hei 7-316092 (corresponding to EP-0632008A1).
  • the polymer of the present invention may be prepared by the method described hereinafter in Examples, known methods or the method of the following reactions (1) ⁇ (3).
  • saccharide (G) may be conjugated to hydrazine in the polymer of the formula (II) described hereinafter
  • 2-Imino-2-methoxyethyl-1-thiosaccharide which is the starting material in the reaction (a) include, for example, 2-imino-2-methoxyethyl-1-thiogalactoside, 2-imino-2-methoxyethyl-1-thiomanoside or 2-imino-2-methoxyethyl-1-thiofucoside of the formula
  • 2-Imino-2-methoxyethyl-1-thiosaccharide is known compound or may be prepared by reacting cyanomethyl-1-thiosaccharide and sodium methoxide in methanol at room temperature (10 ⁇ 25°C.). (see the method described in Biochemistry Vol.15, No.18, 3956-3962 (1976)).
  • the saccharide which is starting material in reaction (b) include, for example, the compound of the formula
  • [0096] (wherein, Q is defined as hereinbefore.) may be prepared by reacting aldehyde at the reductive terminal group of glucose of the saccharide which is used in the reaction and hydrazine in the polymer of the formula (II). This reaction is carried out in a weak acidic condition (e.g. in citrate buffer solution (pH4 ⁇ 6)) at room temperature (10 ⁇ 25° C.).
  • a weak acidic condition e.g. in citrate buffer solution (pH4 ⁇ 6)
  • This reduction is called as reductive amidation. It may be carried out using reductive agent such as sodium borohydride, sodium cyanoborohydride etc. in a weak alkaline condition (e.g. in borate buffer solution (pH8 ⁇ 9)), at 30 ⁇ 50° C.
  • reductive agent such as sodium borohydride, sodium cyanoborohydride etc.
  • borate buffer solution pH8 ⁇ 9
  • an ordinal saccharide may be conjugated to hydrazine.
  • saccharide (G) may be conjugated to hydrazine in the polymer of the formula (II).
  • each L-glutamic acid connecting COOR 1 (wherein, R 1 is defined as hereinbefore), L-glutamic acid COOH, L-glutamic acid NH 2 and L-glutamic acid G (saccharide) may be connected at random in order.) may be prepared.
  • reaction (3) various kinds of reactions will be carried out in accordance with the structure of drugs.
  • Drugs possessing keto group may be conjugated via hydorazon bond which is formed by dehydro-condensation reaction with hydrazine in the polymer of the formula (I-1). This reaction is carried out in a weak acidic condition (e.g. in citrate buffer solution (pH4 ⁇ 6)), at room temperature (10 ⁇ 25° C.).
  • a weak acidic condition e.g. in citrate buffer solution (pH4 ⁇ 6)
  • drugs may be introduced to poly-L-glutamic acid via various kinds of bonds by known method.
  • NH 2 in hydrazine in the group may be capped with saccharide by reacting the polymer prepared in reaction (3) and the same saccharide as introduced in the reaction (2) again, if optionally.
  • obtained products may be purified by conventional techniques. For example, purification may be carried out by distillation at atmospheric or reduced pressure, by high performance liquid chromatography, by thin layer chromatography or by column chromatography using silica gel or magnesium silicate, by washing or by recrystallization. Purification may be carried out after each reaction, or after a series of reactions.
  • the starting materials and reagents in the present invention are known per se or may be prepared by known methods.
  • the polymer of the present invention represented as Polymer P1 possesses capability of migrating into target organs as shown hereinafter in Experiment. It is expected that the said polymer is decomposable in natural condition and that it is safe one, because it is natural high molecule compound. Therefore, the said polymer is useful as a carrier.
  • PLGA poly-L-glutamic acid
  • PGE 1 - PGE 1 bonded to hydrazine or ethylenediamine wherein the said PGE 1 is labeled with 3 H partially, p 0 Gal: 1-thiogalactpyranosyl-2-imino-ethyl, p 0 -HZ-Lac (reductive): a group of the formula
  • MeONa sodium methoxide
  • the carrier polymer of the present invention showed high level of accumulation and long-term accumulation of it in liver.
  • the drug (PGE 1 )-containing polymer of the present invention showed inhibition effect on increasing GPT level in plasma of CCl 4 induced liver damage significantly to compare with the group consisting of saline solution (Control group).
  • the inhibition rate of increasing GPT level in the Invention group was three-time superior to that in the group consisting of free PGE 1 at the corresponding dose.
  • (2) PLGA-HZ (prepared in Reference Example 1) (50 mg) was dissolved in 2N HCl (1 ml). The mixture was neutralized by addition of 2N NaOH. Borate buffer solution (50 mM, pH9.5)(3 ml) was added thereto. The solution was added to the residue obtained in (1). The mixture was stirred for 5 hours at room temperature. The reaction solution was dialyzed, concentrated and freezed to dry to obtain the title compound having the following physical data. In addition, Gal residue was assayed by sulphate-anthron method.
  • Example 2 By the same procedure as Example 2, the title compound having the following physical data was obtained using PLGA-HZ-Lac (reductive/prepared in Example 5).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Polyamides (AREA)

Abstract

Polymers derived from polymers represented by Formula (A) (d is 20˜500; and Rs, which may be the same or different, represent each H, alkyl or benzyl) by substituting a part or all of the consisting peptide bonds by (1) hydrazino-Glu (Formula B), and saccharide-modified Glu (Formula C) or by (2) hydorazino-Glu (Formula B), and saccharide-modified Glu (Formula C), and drug bonded Glu (Formula D). These polymers, which are carriers optionally bonded to drugs capable of migrating into target organs (cells), are useful as medicines.
Figure US20030104989A1-20030605-C00001

Description

    THE FIELD OF THE ART
  • The present invention relates to saccharide-modified polymers which are useful as carriers capable of migrating into target organs (cells), drug-containing polymers using them and the process for the preparation thereof. [0001]
    • BACKGROUND
  • The drug delivery systems into the target organs comprising low-molecular drugs bonded to high-molecular compounds as carriers capable of migrating into target organs have been studied in order to obtain the aimed pharmaceutical effect of the drugs on the target organs and to reduce the side effects of the drugs on the other organs. [0002]
  • For example, it is disclosed that drug delivery systems into liver comprising of drugs modified with the compounds obtained by combination of galactose and proteins or high-molecule compounds based on the fact that the receptors specific for galactose exist in liver parenchymal cell in High-Molecule Vol. 46, No. 11, 843-848 (1997). [0003]
  • In addition, it is disclosed that poly-L-glutamic acid derivatives wherein a part of or all of the consisting peptide bonds in the poly-L-glutamic acid of the formula [0004]
    Figure US20030104989A1-20030605-C00002
  • (wherein, Xa is degree of polymerization of 20˜540, R[0005] a is hydrogen, lower alkyl or benzyl.) are replaced with a group of the formula
    Figure US20030104989A1-20030605-C00003
  • is useful as a carrier of drugs capable of migrating into liver in the Japanese Patent Application Kokai Hei 7-228688. The drugs have been conjugated to carboxyl group in the said glutamic acid via amide bond, ester bond or ion bond etc. directly. Vitamin K5 is described as an example of drugs in this publication. [0006]
  • Further, it is disclosed that polymers of PGE[0007] 1-containing L-glutamic acid derivative (abbreviated as polymer PA) of the formula
    Figure US20030104989A1-20030605-C00004
  • is as high-molecule prodrug of PGE[0008] 1 capable of migrating into liver in International. J. Pharmaceutics, 155, 65-74 (1997). The drug (PGE1) is conjugated to L-glutamic acid via amide bond through ethylenediamine (—NH—CH2CH2—NH—) as a spacer.
  • In the process for the preparation of the said polymer PA, which comprises amidation by condensation between PGE[0009] 1 and ethylenediamine as a spacer (reacting the activated ester of PGE1 with ethylenediamine using carbodiimide (CDI) etc.), the reaction was carried out in an alkaline condition. Therefore, there is a problem that the drug which is unstable in an alkaline condition (e.g. PGE1) would be decomposed and that the introducing rate of drugs into poly-L-glutamic acid does not increase. In this publication, quantity of drugs (PGE1) introduced into one molecule of polymer (degree of polymerization of L-glutamic acid=101) is 1.6 molecule.
  • The present inventors have dissolved such a problem by using hydrazine (—NH—NH—) instead of ethylenediamine (—NH—CH[0010] 2CH2—NH—) as a spacer in the reaction of drugs (e.g. PGE1) and L-glutamic acid. That is to say, the reaction to introduce the drugs (PGE1) is carried out in a weak acidic condition, so it is possible to introduce the drugs constantly, even if it is unstable in an alkaline condition. Based on this reaction, they have improved the introducing rate of drugs (e.g. PGE1) into poly-L-glutamic acid, and then succeeded in synthesis of drugs-containing polymers showing the superior effect. In addition, it has proved that any compounds can be introduced into the polymer constantly by using this reaction. For example, quantity of drugs (PGE1) introduced into one molecule polymer of the present invention (degree of polymerization of L-glutamic acid=97) is 5 molecule, which means the polymer of the present invention has 3-folds superiority in introducing rate of drug to compare with the polymer of the said publication.
  • In addition, the polymer using hydrazine of the present invention shows superiority in both accumulation of drugs into liver after administration and effects of drugs (cytoprotective activity of PGE[0011] 1) to the polymers using ethylelendiamine.
  • Further, there is a merit that such a reaction between hydrazine and the drug (PGE[0012] 1) has been carried out by a simple procedure comprising of only stirring them at room temperature.
    • DISCLOSURE OF THE INVENTION
  • The present invention relates to [0013]
  • (1) the polymer (abbreviated as Polymer P1.) wherein a part of or all of the consisting peptide bonds in the poly-L-glutamic acid of the formula (A) [0014]
    Figure US20030104989A1-20030605-C00005
  • (wherein, degree of polymerization d is 20˜500, R is hydrogen, C1˜6 alkyl or benzyl, with the proviso that each multiple R may be same or different.) are replaced with the group of the formula [0015]  
    Figure US20030104989A1-20030605-C00006
  • (wherein [0016]  
    Figure US20030104989A1-20030605-C00007
  • (wherein, G is a modified saccharide capable of conjugating to hydrazine, m is 1 when [0017]  
    Figure US20030104989A1-20030605-P00900
    is a single bond and m is 0 when
    Figure US20030104989A1-20030605-P00900
    is a double bond.)
  • (wherein, (1) group of the both formula (B) and (C) are essential substituents and when the number of replacement of group of the formula (C) is 2 or more, all the said group are the same.), [0018]  
  • (2) the polymer (abbreviated as Polymer P2.) wherein a part of or all of the consisting peptide bonds in the poly-L-glutamic acid of the formula (A) [0019]
    Figure US20030104989A1-20030605-C00008
  • (wherein, all the symbols are defined as claim 1.) are replaced with the group of the formula [0020]  
    Figure US20030104989A1-20030605-C00009
  • (wherein [0021]  
    Figure US20030104989A1-20030605-C00010
  • is defined as claim 1, [0022]  
    Figure US20030104989A1-20030605-C00011
  • (wherein, D is drug, n is 1 when [0023]  
    Figure US20030104989A1-20030605-P00001
    is a single bond, or n is 0 when
    Figure US20030104989A1-20030605-P00001
    is a double bond.)
  • (wherein, (1) group of the both formula (C) and (D) are essential substituents, [0024]  
  • (2) when the number of replacement of group of the formula (C) or (D) is 2 or more, all the said group of the formula (C) or (D) are the same and (3) the number of replacement of group of the formula (B) may be 0.), and [0025]
  • (3) the process for the preparation thereof. [0026]
    • DETAILED DESCRIPTION OF THE INVENTION
  • Polymer P1 is a carrier polymer capable of migrating into target organs (cells) and Polymer P2 is a drug-containing polymer, which is obtained by utilizing the said carrier polymer, capable of migrating into target organs (cells). [0027]
  • The delivery of the polymer of the present invention into target organs (cells) depends upon the saccharide (represented by G) conjugated to glutamic acid. It is known that various kinds of receptors for saccharides exist in organs (cells) and, new receptors may be found in the future study. It is possible to obtain the drug delivery system into target organs (cells) by choice of saccharide (G) capable of conjugating to the aimed organs (cells) including such known or new receptors. [0028]
  • For example, in case of monosaccharide, galactose receptor, mannose receptor and fucose receptor exist in liver parenchymal cells, liver nonparenchymal cells (endotherial cells and Kupffer cells) and Kupffer cells, respectively, so it is possible to obtain drug delivery system into liver (the said liver cells) by conjugate of galactose, mannose or fucose derivative (corresponds to Polymer P1 and P2 of the present invention in which [0029]
    Figure US20030104989A1-20030605-C00012
  • is a group of the formula of (G[0030] 1), (G2) and (G3) described hereinafter.). For example, in case of oligosacchardies such as di, tri or tetrasaccharides etc. or multi-saccharides, the delivery of the polymer of the present invention into target organs (cells) depends upon the terminal saccharide. For example, the terminal saccharide of lactose which is one of disaccharide (corresponds to Polymer P1 and P2 of the present invention in which
    Figure US20030104989A1-20030605-C00013
  • is a group of the formula (G[0031] 4a) and (G5a).) is galactose, so such a polymer migrates into liver parenchymal cell mainly. As for the aimed saccharide, natural ones or artificial ones which are synthesized may be used.
  • The symbols and degree of polymerization etc. of Polymer P1 and P2 of the present invention are explained in detail as follows: [0032]
  • The symbol d in the formula (A) in Polymer P1 and P2 of the present invention means the degree of polymerization of L-glutamic acid which is a unit of the polymer of the present invention and it is an integer of 20˜500, preferably 40˜300 and more preferably 50˜150. [0033]
  • The number of replacement of group of the formula (B) in Polymer P1 (corresponds to y[0034] 2 described hereinafter.) is 5˜250 and preferably 5˜50.
  • The number of replacement of group of the formula (C) (corresponds to z[0035] 2 described hereinafter.) is 10˜100, and preferably 20˜60.
  • The number of replacement of group of the formula (B) in Polymer P2 (corresponds to y[0036] 3 described hereinafter.) is 0˜250, and preferably 0˜50.
  • The number of replacement of group of the formula (C) (corresponds to z[0037] 3 described hereinafter.) is 10˜100, and preferably 20˜60. The number of replacement of group of the formula (D) (corresponds to w3 described hereinafter.) is 1˜20, and preferably 1˜10.
  • The average of molecule weight of Polymer P1 is 5,000˜150,000. For example, the average of molecule weight of Polymer P1 using monosaccharide [0038]
    Figure US20030104989A1-20030605-C00014
  • is a group of the formula (G[0039] 1), (G2) and (G3) described hereinafter.) or disaccharide such as lactose derivative
    Figure US20030104989A1-20030605-C00015
  • is a group of the formula (G[0040] 4a) and (G5a) described hereinafter.) is 5,000˜100,000 and preferably 10,000˜30,000.
  • C1-6 alkyl in the formula (A) in Polymer P1 and P2 means methyl, ethyl, propyl, butyl, pentyl or hexyl or its isomer. [0041]
  • Each R is preferably, i) hydrogen or the said C1˜6 alkyl (when multiple R are alkyl, they are the same.), ii) hydrogen or benzyl, or iii) hydrogen only, and more preferably, iii) hydrogen only. [0042]
  • The sacchardie represented by G in the formula (C) in Polymer P1 and P2 may be selected in accordance with the receptors which are know or may be found in the future study exist in the organs (cells), as mentioned before. The modified saccharides represented by G capable of conjugating to hydrazine include, for example, 2-iminoethyl-1-thiosaccharide derivatives and saccharides comprising a group wherein the linkage is cleaved etc. [0043]
  • The said 2-iminoethyl-1-thiosaccharide derivative represented by G include, for example, a group of the formula (if it is represented by [0044]
    Figure US20030104989A1-20030605-C00016
    Figure US20030104989A1-20030605-C00017
  • In addition, the said saccharide containing a group, wherein the linkage is cleaved, represented by G include, for example, group of the formula (if it is represented by [0045]
    Figure US20030104989A1-20030605-C00018
  • [0046]
    Figure US20030104989A1-20030605-C00019
  • (wherein, Q is a saccharide chain containing 1˜10 of saccharide.). [0047]
  • Further, 1˜10 of saccharide represented by Q in the above formula include, for example, the saccharide of the formula [0048]
    Figure US20030104989A1-20030605-C00020
  • (wherein, each p, q and r is 0 or an integer of 1˜9.), preferably galactose, mannose and fucose (corresponds to a group in which each p, q, r is 0 in the above formula) and more preferably galactose. [0049]
    Figure US20030104989A1-20030605-C00021
  • is preferably a group of the formula [0050]
    Figure US20030104989A1-20030605-C00022
  • and more preferably group of the formula (G[0051] 1), (G4a) and (G5a).
  • In Polymer P2, glutamic acid and drugs represented by D is conjugated via various kinds of bonds such as hydorazon bond or amide bond etc. through hydrazino (—NH—NH[0052] 2) which is introduced to L-glutamic acid in accordance with the structure of drugs.
  • The drugs represented by D included any drugs, and preferably, the drug which is unstable in an alkaline condition. Such an alkaline condition means pH8˜11 preferably. Of course, it is possible to apply the drugs other than ones which are unstable in an alkaline condition. [0053]
  • Concrete drugs include PGs (e.g. PGEs, PGFs, PGDs), PGIs, naphthyloxyacetic acid derivatives, bicycloalkanoic acid derivatives, guanidinobenzoic acid derivatives, rhodanine acetic acid derivatives, cinnamoic acid derivatives, valproic acid derivatives, Vitamins, anti-allergic agents, anti-vital, anti-cancer agents etc. [0054]
  • PGs include natural PG such as PGE[0055] 1, PGE2, PGF1α, PGF2α, PGD1, PGD2 etc. and its derivatives.
  • For example, natural PGE[0056] 1 and PGE2 are the compounds shown by the following structures, respectively:
    Figure US20030104989A1-20030605-C00023
  • and PGD[0057] 1 and PGD2 are the compounds shown by the following structures, respectively:
    Figure US20030104989A1-20030605-C00024
  • The concrete PGs include the compounds of the following formula [0058]
    Figure US20030104989A1-20030605-C00025
  • (wherein, [0059]
    Figure US20030104989A1-20030605-C00026
  • R[0060] c is hydrogen or various kinds of substituents of carboxyl group such as C1˜12 alkyl, benzyl etc.,
  • A is C2˜10 alkylene (1) in which optional carbon atom may be replaced with CO and/or (2) may have one or more double bond(s), [0061]
  • B is C1˜10 alkyl , C2˜10 alkenyl or C2˜10 alkynyl may be substituted with phenyl, phenoxy or cycloalkyl (wherein each ring may be substituted with C1˜6 alkyl , C2˜6 alkenyl, C2˜6 alkynyl, C1˜6 alkoxy or halogen etc.), [0062]
    Figure US20030104989A1-20030605-C00027
  • is ethylene, trans-vinylene or ethynylene.). [0063]  
  • PGs include preferably PGEs or PGDs (the compounds of the formula [0064]
    Figure US20030104989A1-20030605-C00028
  • in the above formula), more preferably PGEs (the compounds of the formula [0065]
    Figure US20030104989A1-20030605-C00029
  • in the above formula). [0066]
  • Such compounds include PGE[0067] 1, PGE2, 17,20-dimethyl-trans-Δ2-PGE1, 6-keto-17,20-dimethyl-trans-Δ2-PGE1 methyl ester, 16,16-dimethyl-trans-Δ2-PGE1 methyl ester etc.
  • PGEs and PGDs may be conjugated to L-glutamic acid via hydorazon bond at the 9th and 11th position carbon, respectively. For example, PGE[0068] 1 may be conjugated to L-glutamic acid as shown as following structure:
    Figure US20030104989A1-20030605-C00030
  • In addition, PGFs may be conjugated to L-glutamic acid via amide bond between the carboxyl group and amine group of hydrazine which is introduced. [0069]
  • PGIs include natural PGI[0070] 2 and its derivatives, for example, the compounds disclosed in Japanese Patent Application Kokai Sho 54-130543 and Sho 55-64541 (corresponding to GBP-2017699). PGls may be conjugated to L-glutamic acid via amide bond.
  • Naphthyloxyacetic acid derivatives include, for example, the compounds disclosed in Japanese Patent Application Kokai Hei 6-87811 (corresponding to U.S. Pat. No. 5,480,998), for example, [5-[2-[1-phenyl-(3-pyridyl)methylildenaminooxy]ethyl]-7,8-dihydronahthalene-1-yloxy]acetic acid shown by the formula [0071]
    Figure US20030104989A1-20030605-C00031
  • Such a naphthyloxyacetic acid compound may be conjugated to L-glutamic acid via amide bond at the terminal amino group of hydrazine as shown by the following structure: [0072]
    Figure US20030104989A1-20030605-C00032
  • Bicycloalkanoic acid derivatives include, for example, the compounds disclosed in Japanese Patent Application Hei 9-140959. [0073]
  • Guanidinobenzoic acid derivatives include, for example, the compounds disclosed in Japanese Patent Application Kokai Sho 51-138642 (corresponding to U.S. Pat. No. 4,021,472). [0074]
  • Rhodanine acetic acid derivatives include, for example, the compounds disclosed in Japanese Patent Application Kokai Sho 57-40478 (corresponding to U.S. Pat. No. 4,464,382). [0075]
  • Cinnamoic acid derivatives include, for example, the compounds disclosed in 1) Japanese Patent Application Kokai Sho 55-313 (corresponding to U.S. Pat. No. 4,226,878), 2) Japanese Patent Application Kokai Sho 57-131769 (corresponding to U.S. Pat. No. 4,607,046) and 3) International Patent Application No. PCT/JP97/04593. [0076]
  • Valproic acid derivatives include, for example, the compounds disclosed in Japanese Patent Application Kokai Hei 7-316092 (corresponding to EP-0632008A1). [0077]
  • [The process for the Preparation of the Polymer of the Present Invention][0078]
  • The polymer of the present invention may be prepared by the method described hereinafter in Examples, known methods or the method of the following reactions (1)˜(3). [0079]
  • (1) introducing of hydrazine to poly-L-glutamic acid, [0080]
  • (2) introducing of saccharide (corresponds to G), [0081]
  • (3) introducing of drugs (corresponds to D). [0082]
  • In the reaction (1), poly-L-glutamic acid of the formula (A) [0083]
    Figure US20030104989A1-20030605-C00033
  • (wherein, all the symbols are defined as hereinbefore.) [0084]
  • is reacted with hydrazine shown by the formula NH[0085] 2—NH2 in an organic solvent such as dimethylformadmide (DMF) etc, or without solvent at room temperature (10˜25° C.) to prepare the polymer of the formula (II)
    Figure US20030104989A1-20030605-C00034
  • (wherein, d[0086] 1, x1 and y1 are mol (degree of polymerization) of L-glutamic acid connecting COOR1 (wherein, R1 is C1˜6 alkyl or benzyl), L-glutamic acid connecting COOH and L-glutamic acid connecting NH2, respectively. With the proviso that, (1) sum of d1, x1 and y1 equals to d, (2) d1 may be 0, (3) each L-glutamic acid connecting COOR1 (wherein, R1 is defined as hereinbefore.), COOH and NH2 may be bonded at random in order.) (see the method described in J. Appl. Biochem., 2:25 (1980)).
  • In the reaction (2), for example, saccharide (G) may be conjugated to hydrazine in the polymer of the formula (II) described hereinafter [0087]
  • (a) by reacting the polymer of the formula (II) [0088]
    Figure US20030104989A1-20030605-C00035
  • (wherein, all the symbols are defined as hereinbefore.) and 2-imino-2-methoxyethyl-1-thiosaccharide in a weak alkaline condition (e.g. in borate buffer solution (pH9˜10)) or [0089]  
  • (b) by reacting the polymer of the formula (II) and various kinds of saccharides, and then followed by reduction, if optionally. [0090]
  • 2-Imino-2-methoxyethyl-1-thiosaccharide which is the starting material in the reaction (a) include, for example, 2-imino-2-methoxyethyl-1-thiogalactoside, 2-imino-2-methoxyethyl-1-thiomanoside or 2-imino-2-methoxyethyl-1-thiofucoside of the formula [0091]
    Figure US20030104989A1-20030605-C00036
  • 2-Imino-2-methoxyethyl-1-thiosaccharide is known compound or may be prepared by reacting cyanomethyl-1-thiosaccharide and sodium methoxide in methanol at room temperature (10˜25°C.). (see the method described in Biochemistry Vol.15, No.18, 3956-3962 (1976)). [0092]
  • The saccharide which is starting material in reaction (b) include, for example, the compound of the formula [0093]
    Figure US20030104989A1-20030605-C00037
  • (wherein, Q is defined as hereinbefore.). [0094]
  • The polymer of the present invention wherein the formula [0095]
    Figure US20030104989A1-20030605-C00038
  • (wherein, Q is defined as hereinbefore.) may be prepared by reacting aldehyde at the reductive terminal group of glucose of the saccharide which is used in the reaction and hydrazine in the polymer of the formula (II). This reaction is carried out in a weak acidic condition (e.g. in citrate buffer solution (pH4˜6)) at room temperature (10˜25° C.). [0096]
  • And then, the polymer of the present invention wherein the formula [0097]
    Figure US20030104989A1-20030605-C00039
  • (wherein, Q is defined as hereinbefore.) may be prepared by reduction, if optionally. [0098]
  • This reduction is called as reductive amidation. It may be carried out using reductive agent such as sodium borohydride, sodium cyanoborohydride etc. in a weak alkaline condition (e.g. in borate buffer solution (pH8˜9)), at 30˜50° C. By the same procedure, an ordinal saccharide may be conjugated to hydrazine. [0099]
  • By the known reaction other than the above (a) and (b), saccharide (G) may be conjugated to hydrazine in the polymer of the formula (II). [0100]
  • By the series of the above reactions, the polymer of the present invention (corresponds to the said polymer P1) of the formula (I-1) [0101]
    Figure US20030104989A1-20030605-C00040
  • (wherein, d[0102] 2, x2, y2 and z2 are mol (degree of polymerization) of L-glutamic acid connecting COOR1 (wherein, R1 is defined as hereinbefore.), L-glutamic acid connecting COOH, L-glutamic acid connecting NH2 and L-glutamic acid connecting G (saccharide), respectively. With the proviso that (1) sum of d2, x2, y2 and z2 equals to d, (2) d2 may be 0, (3) each L-glutamic acid connecting COOR1 (wherein, R1 is defined as hereinbefore), L-glutamic acid COOH, L-glutamic acid NH2 and L-glutamic acid G (saccharide) may be connected at random in order.) may be prepared.
  • In reaction (3), various kinds of reactions will be carried out in accordance with the structure of drugs. [0103]
  • 1) Drugs possessing keto group (—CO—) may be conjugated via hydorazon bond which is formed by dehydro-condensation reaction with hydrazine in the polymer of the formula (I-1). This reaction is carried out in a weak acidic condition (e.g. in citrate buffer solution (pH4˜6)), at room temperature (10˜25° C.). [0104]
  • 2) Drugs possessing carboxyl group (—COOH) may be conjugated via amide bond which is formed by amidation with amino group at the terminal of hydrazine in the polymer of the formula (I-1). This reaction is well known, it may be carried out, for example, [0105]
  • (1) by the method with using acid halide, [0106]
  • (2) by the method with using mixed acid anhydride, [0107]
  • (3) by the method with using conducing agent (EDC and DCC etc.). [0108]
  • 3) Besides the above, drugs may be introduced to poly-L-glutamic acid via various kinds of bonds by known method. [0109]
  • And then, NH[0110] 2 in hydrazine in the group may be capped with saccharide by reacting the polymer prepared in reaction (3) and the same saccharide as introduced in the reaction (2) again, if optionally.
  • The drug-containing polymer of the present invention (corresponds to Polymer P2) of the formula (I-2) [0111]
    Figure US20030104989A1-20030605-C00041
  • (wherein, d[0112] 3, x3, y3, z3 and w3 are mol (degree of polymerization) of L-glutamic acid connecting COOR1 (wherein, R1 is defined as hereinbefore.), L-glutamic acid connecting COOH, L-glutamic acid connecting NH2, L-glutamic acid connecting G (saccharide) and L-glutamic acid connecting D(drug). With the proviso that (1) the sum of d3, x3, y3, z3 and w3 equals to d, (2) d3 and y3, independently, may be 0, (3) L-glutamic acid connecting COOR1 (wherein, R1 is defined as hereinbefore.), COOH, NH2, G (saccharide) and D (drug) may be conjugated at random in order.) may be prepared by series of these reactions.
  • In each reaction in the present specification, obtained products may be purified by conventional techniques. For example, purification may be carried out by distillation at atmospheric or reduced pressure, by high performance liquid chromatography, by thin layer chromatography or by column chromatography using silica gel or magnesium silicate, by washing or by recrystallization. Purification may be carried out after each reaction, or after a series of reactions. [0113]
  • [Starting Materials and Reagents][0114]
  • The starting materials and reagents in the present invention are known per se or may be prepared by known methods. [0115]
    • Industrial Applicability
  • It has been confirmed that the polymer of the present invention represented as Polymer P1 possesses capability of migrating into target organs as shown hereinafter in Experiment. It is expected that the said polymer is decomposable in natural condition and that it is safe one, because it is natural high molecule compound. Therefore, the said polymer is useful as a carrier. [0116]
  • In addition, it has been confirmed that the drug-containing polymer of the present invention represented as Polymer P2 also possesses capability of migrating into target organs and superior effect as shown hereinafter in Experiments. [0117]
    • BEST MODE FOR CARRYING OUT THE INVENTION
  • The following abbreviations in Experiments and Examples mean as follows: [0118]
  • PLGA: poly-L-glutamic acid, [0119]
  • HZ: hydrazine, [0120]
  • ED: ethylenediamine, [0121]
  • [[0122] 3]PGE1-: PGE1 bonded to hydrazine or ethylenediamine wherein the said PGE1 is labeled with 3H partially, p0 Gal: 1-thiogalactpyranosyl-2-imino-ethyl, p0 -HZ-Lac (reductive): a group of the formula
    Figure US20030104989A1-20030605-C00042
  • DMF: dimethylformamide, [0123]
  • MeOH: methanol, [0124]
  • MeONa: sodium methoxide, [0125]
  • EtOH: ethanol. [0126]
    • Experiment 1 Biodistribution of the Carrier Polymer of the Present Invention (Polymer P1)
  • PLGA-HZ-Gal (prepared in Example 3) and PLGA-HZ-Lac (prepared in Example 5) were labeled with [0127] 111In and were injected into mouse through its tail vein at dose of 1 mg/kg to analyze biodistribution of them. The results are shown in Tables 1 and 2 (Each value in Tables means the percentage of concentration in 1 ml of plasma, the percentage of amount of accumulation in each organ and the percentage of urinary excretion of the said PLGA derivatives (mean±S.D.), respectively at various times after administration.).
    TABLE 1
    Biodistribution data of PLGA-HZ-Gal
    1 min. 5 min. 10 min. 60 min.
    Plasma 47.76 ± 4.87 11.86 ± 4.71  2.41 ± 0.29  0.98 ± 0.16
    Kidney  3.38 ± 0.41  1.61 ± 0.47  0.75 ± 0.13  0.53 ± 0.17
    Spleen  0.02 ± 0.05  0.20 ± 0.10  0.15 ± 0.04  0.08 ± 0.03
    Liver 34.90 ± 0.12 64.80 ± 8.41 75.65 ± 3.12 67.40 ± 3.32
    Lung  0.11 ± 0.03  0.12 ± 0.01  0.09 ± 0.01  0.06 ± 0.02
    Urine  0.04 ± 0.06  3.06 ± 4.33 10.93 ± 1.14 15.30 ± 1.11
  • [0128]
    TABLE 2
    Biodistribution data of PLGA-HZ-Lac (reductive)
    1 min. 5 min. 10 min. 60 min.
    Plasma 42.16 ± 0.56 17.11 ± 5.85  1.99 ± 2.10  0.06 ± 0.03
    Kidney  4.49 ± 0.40  4.67 ± 1.15  2.30 ± 1.45  1.24 ± 0.15
    Spleen  0.10 ± 0.01  0.21 ± 0.02  0.22 ± 0.07  0.19 ± 0.01
    Liver 24.53 ± 4.35 44.16 ± 5.47 59.51 ± 4.56 56.47 ± 3.57
    Lung  0.53 ± 0.10  0.36 ± 0.05  0.11 ± 0.05  0.03 ± 0.00
    Urine  0.16 ± 0.13  5.46 ± 2.89  9.67 ± 3.00  0.91 ± 0.30
  • About 60% of PLGA-HZ-Gal which was administered was accumulated into liver at 10 min. after administration. The same level of accumulation of it was observed in liver at 60 min. [0129]
  • About 60% of PLGA-HZ- Lac which was administered was accumulated into liver at 10 min. after administration. The same level of accumulation of it was observed in liver at 60 min. [0130]
  • From the mentioned, it has proved that the carrier polymer of the present invention showed high level of accumulation and long-term accumulation of it in liver. [0131]
    • Experiment 2 Biodistribution of the Drug-containing Polymer of the Present Invention (Polymer P2)
  • Biodistribution of [[0132] 3]PGE1-HZ-PLGA-HZ-Gal (prepared in Example 4, degree of polymerization=97) and [3H]PGE1-ED-PLGA-ED-Gal (Comparison: the polymer described in International J. Pharmaceutics, 155, 65-74 (1997), degree of polymerization=101) was analyzed by the same procedure as described in Experiment 1. The results are shown in Tables 3 (Invention) and 4 (Comparison) (Each value in Tables means the percentage of concentration in 1 ml of plasma, the percentage of amount of accumulation in each organ and the percentage of urinary excretion of the said [3H]PGE1 derivatives (mean±S.D.), respectively at various times after administration.).
    TABLE 3
    Biodistribution data of [3H]-PGE1-HZ-PLGA-HZ-Gal
    1 min. 5 min. 10 min. 60 min.
    Plasma 14.33 ± 0.75  1.64 ± 0.51  0.40 ± 0.06  0.26 ± 0.07
    Kidney  1.26 ± 0.23  1.23 ± 0.06  0.79 ± 0.14  0.64 ± 0.22
    Spleen  1.11 ± 0.14  1.85 ± 0.10  1.24 ± 0.17  1.84 ± 0.16
    Liver 54.42 ± 0.79 70.39 ± 3.51 80.54 ± 9.52 85.43 ± 3.78
    Lung  1.88 ± 0.46  1.64 ± 0.56  1.00 ± 0.21  0.44 ± 0.18
    Urine  0.00 ± 0.00  1.17 ± 1.01  1.79 ± 0.25  1.45 ± 0.83
  • [0133]
    TABLE 4
    Biodistribution data of [3H]-PGE1-ED-PLGA-ED-Gal
    1 min. 5 min. 10 min. 60 min.
    Plasma 36.55 ± 1.63  6.33 ± 0.84  1.99 ± 0.42  0.00 ± 0.00
    Kidney  9.58 ± 1.46 28.82 ± 2.82 33.25 ± 5.63 13.16 ± 1.32
    Spleen  0.41 ± 0.06  0.37 ± 0.17  0.63 ± 0.27  1.02 ± 0.53
    Liver 27.72 ± 3.81 41.16 ± 2.04 47.19 ± 1.03 45.12 ± 8.21
    Lung  1.97 ± 0.85  1.40 ± 0.13  0.82 ± 0.33  0.69 ± 0.14
    Urine  0.05 ± 0.05  3.77 ± 2.28  2.28 ± 1.61  6.56 ± 3.15
  • As shown in Table 3, 70% of drug which was administered was accumulated into liver at 5 min. after administration. In addition, 85% and 70% of drug were observed to be accumulated to liver at 1 hour and 24 hours after administration, respectively. [0134]
  • On the other hand, in Comparison (Table 4) group, 40% and 45% of drug which was administered were accumulated to liver at 5 min. and 1 hour after administration, respectively. [0135]
  • Therefore, it has proved that it is possible to deliver the drug at the higher concentration continuously into liver using the drug-containing polymer of the present invention. [0136]
    • Experiment 3 Effect of the Drug (PGE1)-containing Polymer of the Present Invention (Polymer P2) on CCl4 Induced Liver Damage
  • A solution of 10% (v/v) of CCl[0137] 4 in sesame oil at dose of 10 ml/kg was administered into mouse abdominal cavity, and then drug (saline solution (Control), Free-PGE1 (Comparison), drug (PGE1)-containing polymer of the present invention PGE1-HZ-PLGA-HZ-Lac (reductive) (prepared in Example 6)) were injected into mouse through its tail vein at the setting dose. After the mouse had been fasted for 18 hours (25° C., water was freely given), blood was collected to assay GPT level (IU/L) in plasma. The results are shown in Table 5.
    TABLE 5
    n (No.
    of animals) GPT level
    Control (saline solution/CCI4 (−)) 3 12.68 ± 1.527
    Control (saline solution/CCI4 (+)) 5 614.56 ± 250.3 
    Free PGE1 (0.065 mg/kg) 5 660.89 ± 218.28
    PGE1-HZ-PLGA-HZ-Lac (1 mg/kg) 4 239.12 ± 77.482
  • As shown in Table 5, the drug (PGE[0138] 1)-containing polymer of the present invention showed inhibition effect on increasing GPT level in plasma of CCl4 induced liver damage significantly to compare with the group consisting of saline solution (Control group). In addition, the inhibition rate of increasing GPT level in the Invention group was three-time superior to that in the group consisting of free PGE1 at the corresponding dose.
    •  REFERENCE EXAMPLES AND EXAMPLES
  • The following Reference Examples and Examples are intended to illustrate, but not limit, the present invention. Each number represented as d[0139] t, xt, yt (t=1, 2, 3), zu (u=2, 3), w3 in the column of degree of polymerization means mol of L-glutamic acid connecting COOR1 (wherein, R1 is C1˜6 alkyl, benzyl.), L-glutamic acid connecting COOH, L-glutamic acid connecting NH2, L-glutamic acid connecting G (galactose form or lactose form) and L-glutamic acid connecting D (PGE1) per 1 mol of polymer.
    • Reference Example 1 Synthesis of PLGA-HZ (Degree of Polymerization: d1=0, x1=29, y1=50)
  • To γ-benzyl-poly-L-glutamic acid (MW: 17,300, degree of polymerization=79) (200 mg), solution of hydrazine ·monohydrate (10 ml) in DMF (3 ml) was added at a dropwise with stirring. The mixture was reacted for 3 hours at room temperature. The reaction solution was dialyzed with dialysis tube (3,500 molecular weight cut-off) (When the inner solution of tube became to be gel, the solution was recovered to be homogenous condition by addition of an adequate quantity of conc. HCl.). Inner solution of tube was ultrafiltered (10,000 molecular weight cut-off), concentrated and freezed to dry to obtain the title compound having the following physical data. [0140]
  • It was confirmed that each benzyl group, which was a protecting group of glutamic acid, was removed entirely by NMR analysis. In addition, hydrazine residue was assayed by β-naphathoquinon-4-sulphonate method. [0141]
  • MW: 10,900; [0142]
  • degree of polymerization: d[0143] 1=0, x1=29, y1=50.
    • Example 1 Synthesis of PLGA-HZ-Gal (Degree of Polymerization: d2=0, x2=29, y2=8, z2=42)
  • (1) To cyanomethyl 1-thiogalacoside (150 mg), MeONa/MeOH (3 ml) was added. The mixture was stirred for 24 hours. MeOH was distilled off under reduced pressure from the mixture. [0144]
  • (2) PLGA-HZ (prepared in Reference Example 1) (50 mg) was dissolved in 2N HCl (1 ml). The mixture was neutralized by addition of 2N NaOH. Borate buffer solution (50 mM, pH9.5)(3 ml) was added thereto. The solution was added to the residue obtained in (1). The mixture was stirred for 5 hours at room temperature. The reaction solution was dialyzed, concentrated and freezed to dry to obtain the title compound having the following physical data. In addition, Gal residue was assayed by sulphate-anthron method. [0145]
  • MW: 20,900; [0146]
  • degree of polymerization: d[0147] 2=0, x2=29, y2=8, z2=42.
    • Example 2 Synthesis of [3H]PGE1-HZ-PLGA-HZ-Gal (degree of Polymerization: d3=0, x3=29, y3=7, z3=42, w3=1)
  • (1) PLGA-HZ-Gal (prepared in Example 1) (22.5 mg) was dissolved in 0.1M acetate buffer solution (pH5.0) (1 ml). [0148]
  • (2) To a solution of iced PGE[0149] 1 (2.5 mg) in EtOH (0° C., 1 ml), a solution of [3H]PGE1 (EtOH: H2O=7:3; 0.5 μCi/ml) (0.1 ml) was added.
  • (3) Stirring the solution prepared in the above (1) at room temperature, the solution obtained in the above (2) was added at a dropwise thereto. 0.1M acetate buffer solution (pH5.0) (0.5 ml) was added thereto to clarify the solution. The solution was stirred for 24 hours at 4° C. After removing the impurities from the reaction mixture, the solution was dialyzed. The dialyzed solution was ultrafiltered (10,000 molecular weight cut-off), concentrated and freezed to dry to obtain the title compound having the following physical data. [0150]
  • MW: 21,200; [0151]
  • degree of polymerization: d[0152] 3=0, x3=29, y3=7, z3=42, w3=1.
    • Example 3 Synthesis of PLGA-HZ-Gal (Degree of Polymerization: d2=0, x2=29, y2=37, z2=31)
  • By the same procedure as Reference Example 1→Example 1, the title compound having the following physical data was obtained using γ-benzyl-poly-L-glutamic acid (degree of polymerization=97). [0153]
  • MW: 20,800; [0154]
  • degree of polymerization: d[0155] 2=0, x2=29, y2=37, z2=31.
    • Example 4 Synthesis of PGE1-HZ-PLGA-HZ-Gal and [3H]PGE1-HZ-PLGA-HZ-Gal (Degree of Polymerization: d3=0, x3=29, y3=32, z3=31, w3=5)
  • PLGA-HZ-Gal (prepared in Example 3) (20 mg) was dissolved in 0.01M acetate buffer solution (pH5.0) (5 ml). Stirring this solution, a solution of PGE[0156] 1 (4 mg) in EtOH (0.5 ml) was added at a dropwise thereto. The mixture was stirred over night at room temperature. The reaction solution was dialyzed by saline solution to obtain the title compound (PGE1-HZ-PLGA-HZ-Gal) having the following physical data. In addition, by the same procedure, the title compound ([3H]PGE1) having the following same physical data was obtained by addition of [3H]PGE1(10 μCi) to the said solution of PGE1 in EtOH. Both compounds were stored as a solution form.
  • MW: 23,000; [0157]
  • degree of polymerization: d[0158] 3=0, x3=29, y3=32, z3=31, w3=5.
    • Example 5 Synthesis of PLGA-HZ-Lac(Reductive/degree of Polymerization: d2=0, x2=35, y2=40, z2=22)
  • PLGA-HZ (MW: 13,300, degree of polymerization: d[0159] 1=0, x1=35, y1=62) (50 mg) which was prepared by the same procedure as Reference Example 1 using γ-benzyl-poly-L-glutamic acid (degree of polymerization=97) was dissolved in 5N NaOH and neutralized to about pH7 by addition of 5N HCl. 0.1M borate buffer solution (pH8.5) was added thereto to become to pH8˜9. Lactose (143 mg) and sodium cyanoborohydride (50 mg) was added thereto. The solution was reacted for one day at 37° C. The reaction solution was purified with dialysis and freezed to dry to obtain the title compound having the following physical data.
  • MW: 20,800; [0160]
  • degree of polymerization: d[0161] 2=0, x2=35, y2=40, z2=22.
    • Example 6 Synthesis of PGE1-HZ-PLGA-HZ-Lac (Reductive/degree of Polymerization: d3=0, x3=35, y3=36, z3=22, w3=4)
  • By the same procedure as Example 2, the title compound having the following physical data was obtained using PLGA-HZ-Lac (reductive/prepared in Example 5). [0162]
  • MW: 22,800; [0163]
  • degree of polymerization: d[0164] 3=0, x3=35, y3=36, z3=22, w3=4.

Claims (10)

1. A polymer wherein a part of or all of the consisting peptide bonds in the poly-L-glutamic acid of the formula (A)
Figure US20030104989A1-20030605-C00043
(wherein, degree of polymerization d is 20˜500, R is hydrogen, C1˜6 alkyl or benzyl, with the proviso that each multiple R may be same or different.) are replaced with the group of the formula
Figure US20030104989A1-20030605-C00044
(wherein
Figure US20030104989A1-20030605-C00045
(wherein, G is a modified saccharide capable of connecting to hydrazine, m is 1 when
Figure US20030104989A1-20030605-P00001
is a single bond and m is 0 when
Figure US20030104989A1-20030605-P00001
is a double bond.)
(wherein, (1) group of the both formula (B) and (C) are essential substituents and when the number of replacement of group of the formula (C) is 2 or more, all the said group are the same.).
2. A polymer wherein a part of or all of the consisting peptide bonds in the poly-L-glutamic acid of the formula (A)
Figure US20030104989A1-20030605-C00046
(wherein, all the symbols are defined as in claim 1.) are replaced with the group of the formula
Figure US20030104989A1-20030605-C00047
(wherein,
Figure US20030104989A1-20030605-C00048
is defined as claim 1,
Figure US20030104989A1-20030605-C00049
(wherein, D is drug, n is 1 when
Figure US20030104989A1-20030605-P00001
is a single bond, or n is 0 when
Figure US20030104989A1-20030605-P00001
is a double bond.)
(wherein, (1) group of the both formula (C) and (D) are essential substituents, (2) the number of replacement of group of the formula (C) or (D) is 2 or more, all the said group of the formula (C) or (D) are the same and (3) the number of replacement of group of the formula (B) may be 0.).
3. A polymer according to claim 1 or 2, wherein
Figure US20030104989A1-20030605-C00050
is
Figure US20030104989A1-20030605-C00051
(in each Formula, Q is saccharide chain containing 1˜10 saccharide.).
4. The polymer according to claim 1 or 2, wherein
Figure US20030104989A1-20030605-C00052
is
Figure US20030104989A1-20030605-C00053
5. A polymer according to claim 2, wherein D is a drug which is unstable in an alkaline condition.
6. A polymer according to claim 2, wherein D is a drug possessing keto group.
7. A polymer according to claim 2, wherein D is PGEs.
8. A polymer according to claim 2, wherein
Figure US20030104989A1-20030605-C00054
is
Figure US20030104989A1-20030605-C00055
9. A polymer according to claim 2, wherein D is a drug possessing carboxyl group.
10. A polymer according to claim 2, wherein
Figure US20030104989A1-20030605-C00056
is
Figure US20030104989A1-20030605-C00057
US10/283,047 1998-02-27 2002-10-30 Carrier polymers migrating into target organs and drug-containing polymers Abandoned US20030104989A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/283,047 US20030104989A1 (en) 1998-02-27 2002-10-30 Carrier polymers migrating into target organs and drug-containing polymers

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JPP.HEI.10-064833 1998-02-27
JP6483398 1998-02-27
US09/623,136 US6500916B1 (en) 1998-02-27 1999-03-02 Carrier polymers migrating into target organs and drug-containing polymers
US10/283,047 US20030104989A1 (en) 1998-02-27 2002-10-30 Carrier polymers migrating into target organs and drug-containing polymers

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP1999/000872 Division WO1999043736A1 (en) 1998-02-27 1999-02-25 Carrier polymers migrating into target organs and drug-containing polymers
US09/623,136 Division US6500916B1 (en) 1998-02-27 1999-03-02 Carrier polymers migrating into target organs and drug-containing polymers

Publications (1)

Publication Number Publication Date
US20030104989A1 true US20030104989A1 (en) 2003-06-05

Family

ID=13269653

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/623,136 Expired - Fee Related US6500916B1 (en) 1998-02-27 1999-03-02 Carrier polymers migrating into target organs and drug-containing polymers
US10/283,047 Abandoned US20030104989A1 (en) 1998-02-27 2002-10-30 Carrier polymers migrating into target organs and drug-containing polymers

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/623,136 Expired - Fee Related US6500916B1 (en) 1998-02-27 1999-03-02 Carrier polymers migrating into target organs and drug-containing polymers

Country Status (4)

Country Link
US (2) US6500916B1 (en)
EP (1) EP1065233A1 (en)
KR (1) KR20010041358A (en)
WO (1) WO1999043736A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276783A1 (en) * 2004-06-10 2005-12-15 Ernest Giralt Lledo Polypeptides with the capacity to entrap drugs and release them in a controlled way
EP1760142A1 (en) 2005-09-02 2007-03-07 The Procter and Gamble Company Laundry Scent Customization
US20070134335A1 (en) * 2005-06-08 2007-06-14 Lledo Ernest G Polypeptides with the capacity to entrap drugs and release them in a controlled way
US20080248097A1 (en) * 2007-02-26 2008-10-09 Kwon Glen S Polymeric micelles for combination drug delivery
US20090232762A1 (en) * 2008-03-11 2009-09-17 May Pang Xiong Compositions for delivery of therapeutic agents
US20090318662A1 (en) * 2006-07-14 2009-12-24 Otsuka Chemical Co., Ltd. Hydrazine storage resin
US20110076308A1 (en) * 2009-09-25 2011-03-31 Kwon Glen S Micelle encapsulation of therapeutic agents

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2465537T (en) 2002-10-10 2016-08-03 Ono Pharmaceutical Co Microspheres comprising ono-1301
WO2006115293A1 (en) * 2005-04-22 2006-11-02 The University Of Tokyo NOVEL BLOCK COPOLYMER USED FOR PREPARING pH-RESPONSIVE POLYMER MICELLE, AND METHOD FOR PRODUCING SAME
JP2007191643A (en) * 2006-01-20 2007-08-02 Mitsui Chemicals Inc Polyamino acid derivative imparted with fixability to living body
KR102091588B1 (en) * 2013-05-27 2020-03-24 주식회사 바이오리더스 Composition for Dispersting or Hydrating Mucus Containing Poly gamma-glutamic acid
KR101507119B1 (en) * 2013-05-31 2015-03-30 주식회사 바이오리더스 Mucoadhesive Poly-γ-glutamic acid Nanomicelles and Drug Delivery Vector Use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985617A (en) * 1974-10-29 1976-10-12 Ajinomoto Co., Inc. Immobilization of biologically active proteins with a polypeptide azide
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US5480998A (en) * 1992-07-21 1996-01-02 Ono Pharmaceutical Co., Ltd. Oxime derivative
US5650270A (en) * 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219564A (en) * 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
WO1992000748A1 (en) 1990-07-06 1992-01-23 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
JPH07228688A (en) * 1994-02-18 1995-08-29 Yamanouchi Pharmaceut Co Ltd Poly-omega-substituted-l-glutamic acid derivative modified with saccharide and its production

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985617A (en) * 1974-10-29 1976-10-12 Ajinomoto Co., Inc. Immobilization of biologically active proteins with a polypeptide azide
US4371673A (en) * 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
US5650270A (en) * 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5480998A (en) * 1992-07-21 1996-01-02 Ono Pharmaceutical Co., Ltd. Oxime derivative

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050276783A1 (en) * 2004-06-10 2005-12-15 Ernest Giralt Lledo Polypeptides with the capacity to entrap drugs and release them in a controlled way
WO2005121215A3 (en) * 2004-06-10 2006-08-10 Farmhispania Polypeptides with the capacity to entrap drugs and release them in a controlled way
US20070134335A1 (en) * 2005-06-08 2007-06-14 Lledo Ernest G Polypeptides with the capacity to entrap drugs and release them in a controlled way
EP1760142A1 (en) 2005-09-02 2007-03-07 The Procter and Gamble Company Laundry Scent Customization
US20090318662A1 (en) * 2006-07-14 2009-12-24 Otsuka Chemical Co., Ltd. Hydrazine storage resin
US20080248097A1 (en) * 2007-02-26 2008-10-09 Kwon Glen S Polymeric micelles for combination drug delivery
US20090232762A1 (en) * 2008-03-11 2009-09-17 May Pang Xiong Compositions for delivery of therapeutic agents
US20110076308A1 (en) * 2009-09-25 2011-03-31 Kwon Glen S Micelle encapsulation of therapeutic agents
US8236329B2 (en) 2009-09-25 2012-08-07 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
US8383136B2 (en) 2009-09-25 2013-02-26 Wisconsin Alumni Research Foundation Micelle encapsulation of therapeutic agents
US8529917B2 (en) 2009-09-25 2013-09-10 Wisconsin Alumni Research Foundation Micelle encapsulation of a combination of therapeutic agents
US8858965B2 (en) 2009-09-25 2014-10-14 Wisconsin Alumni Research Foundation Micelle encapsulation of a combination of therapeutic agents

Also Published As

Publication number Publication date
EP1065233A1 (en) 2001-01-03
KR20010041358A (en) 2001-05-15
WO1999043736A1 (en) 1999-09-02
US6500916B1 (en) 2002-12-31

Similar Documents

Publication Publication Date Title
US6500916B1 (en) Carrier polymers migrating into target organs and drug-containing polymers
US6436386B1 (en) Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
EP1496076B1 (en) Hydrophilic polymer derivate with y type branch and preparation method of it medical composite comprising above compound
US8372422B2 (en) Hydroxyapatite-targeting poly(ethylene glycol) and related polymers
US6620916B1 (en) Modified physiologically active proteins and medicinal compositions containing the same
Hamzavi et al. Modulation of the pharmacokinetic properties of PNA: preparation of galactosyl, mannosyl, fucosyl, N-acetylgalactosaminyl, and N-acetylglucosaminyl derivatives of aminoethylglycine peptide nucleic acid monomers and their incorporation into PNA oligomers
AU649416B2 (en) Glycosaminoglycan-modified protein
EP0125299B1 (en) Glycosylated insulin derivatives
IE883717L (en) Redox systems for brain-targeted drug delivery
JPH0645639B2 (en) Peptide derivative
WO1996023794A1 (en) High molecular weight polymer-based prodrugs
IE890810L (en) Pharmaceutical formulations for parenteral use
KR20010071450A (en) Vitamin b12 derivatives and methods for their preparation
JP3390965B2 (en) Polymer compound containing sugar-linked sphingosine
WO2008052428A1 (en) Preparation method and conjugate with drug molecule thereof
US20030103934A1 (en) Drugs having long-term retention in target tissue
US7708978B2 (en) Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders
US7094872B2 (en) Activated polyethylene glycol esters
KR20190099417A (en) Glucose-sensitive Peptide Hormones
JP2791001B2 (en) Glycosyl-protein derivatives
JPH0782291A (en) Water-soluble anthracycline derivative
JPH07228688A (en) Poly-omega-substituted-l-glutamic acid derivative modified with saccharide and its production
AU2003204343B2 (en) Vitamin B12 derivatives and methods for their preparation
US20040005708A1 (en) Polypeptide derivatives and nucleic acid carriers containing the same
JPH08198891A (en) Sialic acid derivatives and sialyltransferase inhibitors

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE